Evidence map›Paper›PMID 38322474›Full record

ArticleWorld journal of clinical cases2024

Marginal zone lymphoma with severe rashes: A case report.

Si-Jun Bai, Ye Geng, Yi-Nan Gao, Cai-Xia Zhang, Qian Mi, Chen Zhang, Jia-Ling Yang, Si-Jie He, Zhen-Ying Yan, Jian-Xia He

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical cases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Si-Jun BaiDepartment of Hematology, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China.
Ye GengDepartment of Hematology, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China.
Yi-Nan GaoDepartment of Hematology, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China.
Cai-Xia ZhangDepartment of Hematology, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China.
Qian MiDepartment of Hematology, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China.
Chen ZhangDepartment of Hematology, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China.
Jia-Ling YangDepartment of Hematology, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China.
Si-Jie HeDepartment of Hematology, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China.
Zhen-Ying YanDepartment of Hematology, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China.
Jian-Xia HeDepartment of Hematology, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China. hejianxia125@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMarginal zone lymphoma (MZL) is an indolent subtype of non-Hodgkin lymphoma (NHL), which is rare clinically with severe rashes as the initial symptom. CASE SUMMARY: This study reports a case of MZL with generalized skin rashes accompanied by pruritus and purulent discharge. First-line treatment with rituximab combined with zanubrutinib had poor effects. However, after switching to obinutuzumab combined with zanubrutinib, the case was alleviated, and the rashes disappeared.

conclusionFor patients with advanced stage MZL not benefiting from type I anti-CD20 monoclonal antibody (mAb) combination therapy, switching to a type II anti-CD20 mAb combination regimen may be considered. This approach may provide a new perspective in the treatment of MZL.

Indexed as

Case reportExtranodal marginal zone lymphomaMarginal zone lymphomaMucosa-associated lymphoid tissuePrimary cutaneous marginal zone lymphomaRituximab, ObinutuzumabZanubrutinib

Identifiers

PMID38322474
PMCPMC10841955

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.